Why Registration Feasibility Must Start with Market Evidence

Technical feasibility is only one part of the case

A technically registrable formulation can still be a weak investment. It may enter a crowded mode-of-action segment, require a price that the channel cannot support, depend on claims that are difficult to demonstrate, or reach the market through partners with insufficient technical capability.

For this reason, RAI frames the decision before collecting data: what must be true for this product to recover its registration, launch and working-capital investment? The answer becomes the research agenda.

Build evidence around four commercial questions

• Demand — which crop–pest–province combinations have an important and persistent problem?
• Competition — what active ingredients, formulations, brands, packs and price tiers define the current standard?
• Channel — who influences adoption, who carries inventory and credit, and what proof does each participant require?
• Economics — can landed cost, gross-to-net price, channel margin, credit days and field investment produce an acceptable downside case?

National market size is not enough

Top-down market values are useful for orientation but weak for registration prioritisation. The relevant market is rarely ‘Indonesia insecticides’ or even ‘rice insecticides’. It is a narrower combination of target pest, crop calendar, geography, treatment window, user segment, channel route and realistic claim.

A smaller but clearly defined beachhead can be more valuable than a large theoretical market. It allows the principal to design trials, evidence, pack sizes, partner coverage and launch resources around a segment where adoption can actually be proven.

Use a weighted decision scorecard

A scorecard prevents one attractive data point from dominating the decision. RAI tests regulatory feasibility, market need, differentiation, economics, supply control and partner readiness. Each dimension has a minimum evidence standard and an explicit weight.

• Go — no unresolved red regulatory or data-rights item, with a credible base and downside case.
• Hold — potentially attractive, but one or more evidence gaps must be closed before commitment.
• No-go — the market, proof, economics or control package does not justify registration investment.

A no-go decision can be valuable. It protects capital, management attention and registration capacity for products with a stronger right to win.

Feasibility should shape the registration plan

Commercial evidence should determine the priority crop, claims, trial design, proof ladder and initial geography. It should also influence whether the principal proceeds with one product, a solution portfolio or no registration at all. Registration and commercial strategy are therefore linked, while their technical responsibilities and budgets remain clearly separated.